Barinthus Biotherapeutics

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates for chronic infectious diseases, autoimmunity and cancer. 

layoffs cut staff reduction workforce
Biotech

Barinthus lays off 25%, sidelines prostate cancer program

Barinthus used positive data from a pair of phase 2 trials for its hepatitis B therapy as justification for jettisoning a quarter of its workforce.
James Waldron Jun 13, 2024 5:30am
hawaii parasail ocean

BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders

May 3, 2024 8:30am
arrow miss target fail attempt try

Barinthus HPV drug doesn't prove efficacy

Apr 19, 2024 9:50am
shot in the arm vaccine strong covid booster

Barinthus' gets $35M booster from CEPI to develop MERS shot

Dec 21, 2023 10:10am
The silhouette of a miner digging

Hepatitis B drug developers chart slow progress, just like hep C

Nov 14, 2023 9:05am
Graphic image of a compass above an unfolded map Orange background color

Vaccitech reemerges as Barinthus with hep B data

Nov 10, 2023 9:30am